Marker Therapeutics, Inc.
Pioneering a Multi-Antigen Approach
20 employees · est. 2018 · Houston, United States
Nkarta, Inc.
A New Way Forward for Autoimmune Disease
157 employees · est. 2015 · South San Francisco, United...
Nkarta, Inc. is the older company (2018 vs 2015); Nkarta, Inc. is the larger of the two.
1 signal in the last 90 days
Side-by-Side Comparison
| Metric | Marker Therapeutics, Inc. | Nkarta, Inc. |
|---|---|---|
| Founded | ||
| Founded | 2018 | 2015 older |
| Headquarters | ||
| Headquarters | Houston, United States | South San Francisco, United States |
| Employees | ||
| Employees | 20 | 157 larger |
| Industry | ||
| Industry | Biotechnology, Health and Wellness | Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Grant | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $98.60M | $595.00M |
| Funding Rounds | ||
| Funding Rounds | 5 | 4 |
| Services | ||
| Services | Development of Multi-Antigen Recognizing (MAR) T cell therapies, Clinical trials for novel therapies, Research and development in immunotherapy | Development of immunotherapy drugs, Conducting clinical trials, Research and development of NK cell technology |
| Target Customers | ||
| Target Customers | Patients with lymphoma, Individuals with blood cancers, Patients with solid tumors, Healthcare providers, Medical researchers | Patients with autoimmune diseases, Healthcare providers, Medical researchers |
| Taxonomy | ||
| Taxonomy | Immuno-Oncology, T Cell-based Immunotherapies, Hematological Malignancies, Solid Tumor Indications, Multi-antigen Approach, Non-engineered T Cells, Tumor-associated Antigens, Cell Therapy Technology, Cost-effective Manufacturing, Reduced Toxicity, Clinical-stage Company, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Adoptive T Cell Therapy | Allogeneic NK Cells, Cell Therapy, Immuno-Oncology, Tumor Targeting, Cell Engineering, Cryopreservation, Cell Expansion, Hematologic Malignancies, Solid Tumor Malignancies, Therapy Manufacturing, Cancer Research, Natural Killer Cells, Oncology Therapeutics, Autoimmune Disease Treatment |
| Website | ||
| Website | markertherapeutics.com | nkartatx.com |
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., founded in 2018, is making significant strides in the fields of Biotechnology and Health and Wellness. Headquartered in the United States, the company is driven by the slogan "Pioneering a Multi-Antigen Approach," focusing on the development of advanced T cell-based immuno...
About Nkarta, Inc.
Nkarta, Inc., founded in 2015, is at the forefront of innovative biotechnology solutions aimed at tackling autoimmune diseases. Their slogan, "A New Way Forward for Autoimmune Disease", reflects their pioneering approach in the Biotechnology and Health Care sectors. The company specializes in devel...
We will tell you when either one moves
BounceWatch watches Marker Therapeutics, Inc. and Nkarta, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Marker Therapeutics, I... and Nkarta, Inc. — by email.
Frequently Asked Questions
Compare Marker Therapeutics, Inc. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Marker Therapeutics, Inc. on 9 Jun 2026, and Nkarta, Inc. on 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
